Kymriah, approved recently by the F.D.A., with a $475,000 price tag, is first of a coming wave of treatments whose expected prices have alarmed economists, scientists and insurers.
By GINA KOLATA from NYT Health http://ift.tt/2jinaom
via IFTTT
Drugs (Pharmaceuticals), Health Insurance and Managed Care, Genetic Engineering
Source The New York Times
Làm đẹp Blog 247
Không có nhận xét nào:
Đăng nhận xét